Results 211 to 220 of about 1,303,402 (309)
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Cinematic Rendering Using Photon Counting CT Angiography of a Repaired Complex Aortic Dissection with Type IIIa Endoleak. [PDF]
Methodist Debakey Cardiovasc JForouzannia SA, Umair M.
europepmc +1 more source
LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology, EarlyView.Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix +13 more
wiley +1 more source
Immersive teaching model for traditional Chinese opera costume design based on virtual reality: digital cultural heritage, inheritance, and innovation. [PDF]
Sci RepSu Z.
europepmc +1 more source
Molecular Oncology, EarlyView.Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
A Survey of 3D Reconstruction: The Evolution from Multi-View Geometry to NeRF and 3DGS. [PDF]
Sensors (Basel)Liu S, Yang M, Xing T, Yang R.
europepmc +1 more source
MONITORING OF INFORMATION SERVICE RENDERING BY GOVERNMENT AUTHORITIES AND ITS CONSEQUENCES
, 2018 Ivan V. Petrin, Irina V. Pogodina
openalex +1 more source
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
BirdNeRF: fast neural reconstruction of large-scale scenes from aerial imagery. [PDF]
Sci RepZhang H, Xue Y, Liao M, Lao Y.
europepmc +1 more source